Status:
COMPLETED
Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
Brief Summary
This study is conducted in Europe. The objective of this observational study is to evaluate the number of serious side effects, when initiating NovoMix® treatment in patients with type 2 diabetes who ...
Eligibility Criteria
Inclusion
- Type 2 diabetes mellitus
Exclusion
- Known or suspected allergy to study product or related products.
- Pregnancy or breastfeeding or intention of becoming pregnant within the next 6 months.
Key Trial Info
Start Date :
October 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
611 Patients enrolled
Trial Details
Trial ID
NCT00775736
Start Date
October 1 2008
End Date
January 1 2011
Last Update
January 11 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Brussels, Belgium, 1070
2
Novo Nordisk Investigational Site
Luxembourg, Luxembourg